Altamira Therapeutics Profit Margin

The latest profit margin for CYTO is 4482.79% as of June 2023. That compares with -2810.27% in the prior-year period — up 259.5% year over year. That is above the Healthcare sector average of 14.34%. Investors often review this figure alongside Altamira Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYTO's profit margin moved from -2810.27% to 4482.79% — a 259.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Altamira Therapeutics's valuation or profitability profile.

Against Healthcare companies, CYTO currently prints 4482.79% for profit margin, while the sector average sits near 14.34%. That is roughly 31150.4% above the sector mean. Large gaps often invite a closer look at Altamira Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Altamira Therapeutics converts resources into returns. At 4482.79%, CYTO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2810.27% in the prior-year period — up 259.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CYTO's profit margin (4482.79%), review year-over-year change from -2810.27%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.